Polyclonal glycine receptor aAbs: a challenge for personalized epitope characterization

Area of Science:

• Neuroimmunology
• Molecular biology
• Autoimmunity

Background:

• Patients with glycine receptor (GlyR) autoantibodies (aAbs) suffer from debilitating diseases like stiff-person syndrome (SPS), with current treatments lacking specificity.
• Existing research has mapped only one common epitope for GlyR aAbs in the GlyRα1 subunit's N-terminal region, despite some patient sera binding other GlyR subunits (GlyRα2, GlyRα3, GlyRβ).
• Identifying additional epitopes is critical for developing more targeted and effective therapeutic strategies.

Purpose of the Study:

• To identify additional antibody (aAb) epitopes on glycine receptors (GlyRs) beyond the previously known N-terminal site.
• To investigate the role of specific amino acid residues in GlyR subunits (GlyRa1 and GlyRa3) in aAb binding.
• To assess the potential for epitope characterization in guiding future therapeutic interventions for GlyR aAb-associated diseases.

Main Methods:

• Constructed GlyRa1 and GlyRa3 variants using site-directed mutagenesis based on amino acid differences in their extracellular domains.
• Employed peptide microarrays to identify key residues involved in aAb binding, focusing on a known epitope (⁹⁶PDLFFANEKS¹⁰⁵).
• Utilized two overlapping peptides for aAb neutralization assays in cell-based experiments.

Main Results:

• Identified specific amino acid sequences in the extracellular domain of GlyRs that represent additional aAb epitopes or are involved in aAb binding.
• Demonstrated successful neutralization of specific GlyRb aAbs using a patient serum and a peptide targeting the region ⁹⁶PDLFFANEKSANFHDV¹¹¹.
• Observed reduced, but not complete, neutralization of GlyRa aAbs when using patient sera targeting the ⁹⁶PDLFFANEKS¹⁰⁵ epitope with overlapping peptides.

Conclusions:

• GlyR aAbs exhibit polyclonal binding or target conformational epitopes, indicating patient-specific binding patterns.
• Defined critical residues involved in aAb binding, explaining the difficulty in identifying a single common binding site.
• Epitope characterization is essential for developing patient-specific diagnostics and targeted therapies for GlyR aAb-associated conditions.